On the Surface: a New Path to Finding and Clearing Aged Cells

The Problem Early studies show that destroying senescent, or old and dysfunctional, cells can delay or even reverse diseases of aging and extend lifespan. The primary strategy for turning this into a therapy has been “senolytic” drugs that target signaling pathways that senescent cells need for survival. The Goal An alternative approach, targeting senescent cells …

Read more

Read more...

A Better Way to Create Rejuvenation Therapies

The Problem IPF is linked to the accumulation of senescent, or old, cells in the lung, creating scar tissue (fibrosis) which progressively stiffens them. This disables the patient, eventually suffocating them within 2-4 years. IPF creates a high burden of senescent cells in the lungs, and removing senescent cells powerfully impacts the disease. Previous drug …

Read more

Read more...

Boosting Natural Defenses: Modifying Immune Cells to Target Senescence

The Problem The immune system, including natural killer cells (NK cells), has an ability to patrol for and destroy senescent, or aged cells. However, this protective function deteriorates over time, permitting senescent cells to accumulate in our tissues and drive age-related disease. Drugs used to destroy senescent cells – senolytics – use a brute-force method …

Read more

Read more...

Senolytics in Aging Muscle: Could the Cure Be Worse than the Disease?

Skeletal muscles are organized into long fibers, and when a fiber breaks the entire fiber is often lost. This made a supporter worry that senolytic therapies might break a muscle fiber and eliminate precious fibers in aging muscles. It appears that the injury at the heart of the questioner’s worry does not happen in practice.

Read more...

An Oil Change is Not a Gasket Change: Insights from the Interaction of “Old Blood” and Senolytic Therapy

When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.

Read more...

Kneecapped by Aging: New and Scrutinized Science Suggests Why the UNITY Osteoarthritis Trial Failed

UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can